Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Alisertib lung small cell carcinoma not applicable detail...
Unknown unknown Alisertib + Taxol lung small cell carcinoma not applicable detail...
TP53 inact mut APR-246 lung small cell carcinoma sensitive detail...
RET wild-type Vandetanib lung small cell carcinoma sensitive detail...
MET over exp Ponatinib lung small cell carcinoma sensitive detail...
RET M918T Ponatinib lung small cell carcinoma sensitive detail...
RET wild-type Ponatinib lung small cell carcinoma sensitive detail...
RET M918T Vandetanib lung small cell carcinoma sensitive detail...
Unknown unknown Etoposide + NVP-ADW742 lung small cell carcinoma not applicable detail...
FGFR1 amp Debio 1347 lung small cell carcinoma sensitive detail...
TP53 Y163C APR-246 + Cisplatin lung small cell carcinoma sensitive detail...
PDGFRA amp Ponatinib lung small cell carcinoma sensitive detail...
Unknown unknown Sunitinib lung small cell carcinoma not applicable detail...
RB1 loss Trilaciclib lung small cell carcinoma resistant detail...
RB1 loss Trilaciclib + Topotecan lung small cell carcinoma sensitive detail...
FGFR1 amp AZD4547 lung small cell carcinoma sensitive detail...
Unknown unknown Navitoclax + Pictilisib lung small cell carcinoma not applicable detail...
Unknown unknown Doxorubicin + SLCB050 lung small cell carcinoma not applicable detail...
Unknown unknown BDA-366 lung small cell carcinoma not applicable detail...
TP53 S241F APR-246 lung small cell carcinoma sensitive detail...
TP53 R273L APR-246 lung small cell carcinoma sensitive detail...
FGFR1 amp RO4987655 lung small cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung small cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung small cell carcinoma no benefit detail...
Unknown unknown STA-8666 lung small cell carcinoma not applicable detail...
Unknown unknown Ganetespib lung small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + STA-8666 lung small cell carcinoma not applicable detail...
FGFR1 rearrange AZD4547 lung small cell carcinoma sensitive detail...
FGFR1 amp E7090 lung small cell carcinoma sensitive detail...
Unknown unknown Bevacizumab + Cisplatin + Etoposide lung small cell carcinoma not applicable detail...
ALK rearrange RB1 C706F TP53 loss Lorlatinib lung small cell carcinoma predicted - resistant detail...
Unknown unknown Vandetanib lung small cell carcinoma no benefit detail...
Unknown unknown Talazoparib lung small cell carcinoma not applicable detail...
FGFR1 amp AZD4547 + BKM120 lung small cell carcinoma sensitive detail...
FGFR1 amp GSK3052230 lung small cell carcinoma sensitive detail...
FGFR1 amp Cisplatin + Etoposide + GSK3052230 lung small cell carcinoma sensitive detail...
Unknown unknown Sacituzumab govitecan lung small cell carcinoma not applicable detail...
Unknown unknown Doxorubicin + Lurbinectedin lung small cell carcinoma not applicable detail...
FGFR1 amp MET over exp BGJ398 lung small cell carcinoma resistant detail...
FGFR1 amp MET over exp BGJ398 + Crizotinib lung small cell carcinoma sensitive detail...
FGFR1 amp MET over exp BGJ398 + EMD 1214063 lung small cell carcinoma sensitive detail...
Unknown unknown T-3775440 lung small cell carcinoma not applicable detail...
Unknown unknown Nivolumab lung small cell carcinoma not applicable detail...
Unknown unknown BAY1000394 lung small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Etoposide + Roniciclib lung small cell carcinoma not applicable detail...
KRAS G12V RMC-4550 lung small cell carcinoma predicted - resistant detail...
Unknown unknown Atezolizumab + Carboplatin + Etoposide lung small cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00926640 Phase I Belinostat + Cisplatin + Etoposide A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Completed
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting
NCT01450761 Phase III Cisplatin Ipilimumab Carboplatin Etoposide Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed
NCT01579929 Phase I Cisplatin + Etoposide + Sonidegib Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Completed
NCT01587703 Phase I GSK525762 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Active, not recruiting
NCT01638546 Phase II Temozolomide Veliparib Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Completed
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed
NCT01722292 Phase Ib/II Taladegib Carboplatin + Etoposide A Study of LY2940680 in Small Cell Lung Cancer Terminated
NCT01737502 Phase II Auranofin + Sirolimus PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer Recruiting
NCT01831089 Phase I Lurbinectedin + Paclitaxel + Bevacizumab Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01859741 Phase Ib/II Cisplatin Etoposide Carboplatin Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) Completed
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed
NCT01928394 Phase Ib/II Ipilimumab Nivolumab A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02034123 Phase I GSK2879552 Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma Terminated
NCT02038647 Phase II Paclitaxel Alisertib Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) Completed
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated
NCT02152059 Phase II Nintedanib A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy Withdrawn
NCT02157792 Phase I Cisplatin Etoposide VX-970 Gemcitabine An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy Recruiting
NCT02161419 Phase II BAY1000394 RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer Terminated
NCT02200757 Phase II Aldoxorubicin Topotecan Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Unknown status
NCT02247349 Phase Ib/II BMS-986012 BMS-986012 + Nivolumab BMS-986012 in Relapsed/Refractory SCLC Active, not recruiting
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed
NCT02261805 Phase Ib/II Aldoxorubicin + Ganetespib A Phase I/II Study of Ganetespib in Combination With Doxorubicin Terminated
NCT02289690 Phase I Carboplatin + Etoposide + Veliparib Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer Active, not recruiting
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated
NCT02351505 Phase II Selinexor Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer Terminated
NCT02359019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy Active, not recruiting
NCT02402920 Phase I Carboplatin + Etoposide + Pembrolizumab Cisplatin Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer Recruiting
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Recruiting
NCT02446704 Phase Ib/II Olaparib Temozolomide Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02472977 Phase Ib/II Nivolumab Ulocuplumab Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Terminated
NCT02481830 Phase III Amrubicin Nivolumab Topotecan Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer Active, not recruiting
NCT02487095 Phase Ib/II VX-970 Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Recruiting
NCT02498613 Phase II Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02499770 Phase Ib/II Carboplatin + Etoposide Trilaciclib G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Active, not recruiting
NCT02514447 Phase Ib/II Trilaciclib Topotecan Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Active, not recruiting
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Recruiting
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting
NCT02538666 Phase III Ipilimumab Nivolumab A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) Active, not recruiting
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Recruiting
NCT02579226 Phase I Irinotecan AZD2811 A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors Recruiting
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02649673 Phase Ib/II LCL161 + Topotecan LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies Recruiting
NCT02658214 Phase I Carboplatin + Gemcitabine Carboplatin + nab-paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Durvalumab + Tremelimumab Paclitaxel + Carboplatin Carboplatin + Etoposide Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting
NCT02660034 Phase I BGB-A317 + Pamiparib The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors Recruiting
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02674568 Phase II Rovalpituzumab Tesirine Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) Completed
NCT02701400 Phase II MEDI0562 + Tremelimumab Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer Recruiting
NCT02734004 Phase Ib/II Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02735980 Phase II Prexasertib A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer Active, not recruiting
NCT02748889 Phase Ib/II Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer Terminated
NCT02763579 Phase III Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) Active, not recruiting
NCT02815592 Phase Ib/II Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide Trial of BMS-986012 in Combination With Platinum and Etoposide Active, not recruiting
NCT02819999 Phase I Rovalpituzumab Tesirine + Cisplatin + Etoposide Rovalpituzumab Tesirine A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer Active, not recruiting
NCT02874664 Phase I Rovalpituzumab Tesirine A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Completed
NCT02899728 Phase II Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Suspended
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02934503 Phase II Carboplatin + Cisplatin + Etoposide + Pembrolizumab Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) Recruiting
NCT02936323 PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting
NCT02963090 Phase II Pembrolizumab + Topotecan Pembrolizumab Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Active, not recruiting
NCT03026166 Phase I Rovalpituzumab Tesirine + Nivolumab + Ipilimumab Rovalpituzumab Tesirine + Nivolumab A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer Active, not recruiting
NCT03033511 Phase III Rovalpituzumab Tesirine + Dexamethasone A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU) Recruiting
NCT03041311 Phase II Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) Active, not recruiting
NCT03043599 Phase Ib/II Nivolumab + Ipilimumab Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Active, not recruiting
NCT03043872 Phase III MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide Carboplatin + Cisplatin + Durvalumab + Etoposide Carboplatin + Cisplatin + Etoposide Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) Active, not recruiting
NCT03061812 Phase III Rovalpituzumab Tesirine Topotecan Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) Active, not recruiting
NCT03066778 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Active, not recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03080311 Phase I APG-1252 A Study of APG-1252 in Patients With SCLC or Other Solid Tumors Recruiting
NCT03085849 Phase I Guadecitabine + Durvalumab + Tremelimumab SGI-110 Plus Durvalumab/Tremelimumab in SCLC Completed
NCT03092934 Phase Ib/II AK-01 A Study of AK-01 in Solid Tumors Active, not recruiting
NCT03116971 Phase Ib/II MSC2490484A + Cisplatin + Etoposide MSC2490484A Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) Terminated
NCT03134638 Phase I SY-1365 A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors Recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03179436 Phase I MK-1308 + Pembrolizumab Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001) Recruiting
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03319940 Phase I AMG 757 Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer Recruiting
NCT03325816 Phase Ib/II Nivolumab Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Active, not recruiting
NCT03334487 Phase III Rovalpituzumab Tesirine + Dexamethasone Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer Withdrawn
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Active, not recruiting
NCT03365791 Phase II LAG525 PDR001 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03366103 Phase Ib/II Navitoclax + Vistusertib Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Recruiting
NCT03371979 Phase Ib/II Pegzilarginase + Pembrolizumab Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer Recruiting
NCT03382561 Phase II Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer Active, not recruiting
NCT03402880 Phase II Epacadostat + Pembrolizumab ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Withdrawn
NCT03406715 Phase II Ad.p53-DC vaccine + Ipilimumab + Nivolumab Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) Recruiting
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
NCT03509012 Phase I MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide Carboplatin + Cisplatin + Durvalumab + Pemetrexed Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Recruiting
NCT03532880 Phase I Olaparib A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03554473 Phase Ib/II M7824 + Topotecan M7824 + Temozolomide M7824 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Recruiting
NCT03575793 Phase Ib/II Ipilimumab + Nivolumab + Plinabulin Nivolumab + Ipilimumab A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Recruiting
NCT03639194 Phase I ABBV-181 + SC-011 SC-011 A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Recruiting
NCT03662074 Phase II Gemcitabine + Nivolumab Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer Recruiting
NCT03670056 Phase II Nivolumab + Ipilimumab A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy Not yet recruiting
NCT03672773 Phase II Talazoparib + Temozolomide Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer Recruiting
NCT03703297 Phase III Durvalumab Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Recruiting
NCT03728361 Phase II Nivolumab + Temozolomide Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Recruiting
NCT03830918 Phase Ib/II Niraparib + Temozolomide Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy Not yet recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Not yet recruiting